Rare genetic diseases are challenging for patients and their families—made all the more overwhelming because symptoms tend to appear soon after birth. To date, there haven’t been many reliable ...
MarketBeat on MSN
CRISPR Therapeutics gains after earnings as pipeline hope grows
CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings on Feb. 13. At first glance, that may seem contradictory. The company ...
CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...
A version of this Priestley Medal address will be presented at the American Chemical Society Spring 2026 meeting ...
In the wake of the germline editing controversy, when Chinese scientist He Jianku illegally edited the embryos of human twins ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results